1. Akinyemiju T, Abera S, Ahmed M, et al. The Burden of
primary liver cancer and underlying etiologies from 1990 to
Vol. 22, No. 2
7.
2015 at the global, regional, and national level: Results from
the Global Burden of Disease Study 2015. JAMA Oncol 2017;
3:1683–1691.
Tang A, Hallouch O, Chernyak V, Kamaya A, Sirlin CB.
Epidemiology of hepatocellular carcinoma: target population
for surveillance and diagnosis. Abdom Radiol (NY) 2018;
43:13–25.
Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for
staging and treatment: the BCLC update and future prospects.
Semin Liver Dis 2010; 30:61–74.
Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular
carcinoma. Hepatology 2004; 40:1352–1360.
Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular
carcinoma locoregional therapies for patients in the waiting
list. Impact on transplantability and recurrence rate. J Hepatol
2013; 58:609–618.
Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance
of objective response according to EASL criteria and
mRECIST criteria in hepatocellular carcinoma patients treated
with loco-regional therapies: A literature-based meta-analysis.
PLoS One 2015; 10:e0133488.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines
to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of
Cancer, National Cancer Institute of the United States,
217
Y. Tsujita et al.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
218
National Cancer Institute of Canada. J Natl Cancer Inst 2000;
92:205–216.
WHO handbook for reporting results of cancer treatment.
Geneva: World Health Organization, 1979; Offset Publication
No. 48. (Accessed: July 1, 2022)
Park JW, Chen M, Colombo M, et al. Global patterns of
hepatocellular carcinoma management from diagnosis to
death: the BRIDGE Study. Liver Int 2015; 35:2155–2166.
Forner A, Ayuso C, Varela M, et al. Evaluation of tumor
response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2009; 115:616–623.
Bruix J, Sherman M, Llovet JM, et al. Clinical management of
hepatocellular carcinoma. Conclusions of the Barcelona-2000
EASL conference. European Association for the Study of the
Liver. J Hepatol 2001; 35:421–430.
Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl
Cancer Inst 2008; 100:698–711.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;
30:52–60.
Lencioni R, Montal R, Torres F, et al. Objective response by
mRECIST as a predictor and potential surrogate end-point of
overall survival in advanced HCC. J Hepatol 2017; 66:1166–
1172.
Kudo M, Montal R, Finn RS, et al. Objective response predicts
survival in advanced hepatocellular carcinoma treated with
systemic therapies. Clin Cancer Res 2022; 28:3443–3451.
Galle PR, Forner A, Llovet JM, et al. Management of hepatocellular carcinoma. J Hepatol 2018; 69:182–236.
American College of Radiology. LI-RADS version 2018.
(Accessed: July 1, 2022)
Gupta P, Bansal A, Das GC, et al. Diagnostic accuracy of liver
imaging reporting and data system locoregional treatment
response criteria: A systematic review and meta-analysis. Eur
Radiol 2021; 31:7725–7733.
Huh YJ, Kim DH, Kim B, Choi JI, Rha SE. Per-feature accuracy of liver imaging reporting and data system locoregional
treatment response algorithm: A systematic review and metaanalysis. Cancers (Basel) 2021; 13:4432.
Shropshire EL, Chaudhry M, Miller CM, et al. LI-RADS treatment response algorithm: Performance and diagnostic accuracy. Radiology 2019; 292:226–234.
Park S, Joo I, Lee DH, et al. Diagnostic performance of LI-RADS
treatment response algorithm for hepatocellular carcinoma:
Adding ancillary features to MRI compared with enhancement
patterns at CT and MRI. Radiology 2020; 296:554–561.
Kim SW, Joo I, Kim HC, et al. LI-RADS treatment response
categorization on gadoxetic acid-enhanced MRI: diagnostic
performance compared to mRECIST and added value of
ancillary features. Eur Radiol 2020; 30:2861–2870.
Sugimoto K, Moriyasu F, Kamiyama N, et al. Analysis of
morphological vascular changes of hepatocellular carcinoma
by microflow imaging using contrast-enhanced sonography.
Hepatol Res 2008; 38:790–799.
Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H.
Phagocytosis of ultrasound contrast agent microbubbles by
Kupffer cells. Ultrasound Med Biol 2007; 33:318–325.
25. Kong S, Yue X, Kong S, Ren Y. Application of contrastenhanced ultrasound and enhanced CT in diagnosis of liver
cancer and evaluation of radiofrequency ablation. Oncol Lett
2018; 16:2434–2438.
26. Kudo M, Hatanaka K, Maekawa K. Newly developed novel
ultrasound technique, defect reperfusion ultrasound imaging,
using sonazoid in the management of hepatocellular carcinoma. Oncology 2010; 78(Suppl1): 40–45.
27. Chen CS, Li FK, Guo CY, et al. Tumor vascularity and lipiodol
deposition as early radiological markers for predicting risk of
disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
Oncotarget 2016; 7:7241–7252.
28. Matsui Y, Horikawa M, Jahangiri Noudeh Y, Kaufman JA,
Kolbeck KJ, Farsad K. Baseline tumor lipiodol uptake after
transarterial chemoembolization for hepatocellular carcinoma: Identification of a threshold value predicting tumor
recurrence. Radiol Oncol 2017; 51:393–400.
29. Park C, Gwon DI, Chu HH, Kim JW, Kim JH, Ko GY.
Correlation of tumor response on CT with pathologically
proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold
value of intratumoral Lipiodol accumulation predicting tumor
necrosis. Abdom Radiol (NY) 2021; 46:3729–3737.
30. Johnson TR, Krauss B, Sedlmair M, et al. Material differentiation by dual energy CT: initial experience. Eur Radiol 2007;
17:1510–1517.
31. Lee JA, Jeong WK, Kim Y, et al. Dual-energy CT to detect
recurrent HCC after TACE: initial experience of color-coded
iodine CT imaging. Eur J Radiol 2013; 82:569–576.
32. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C,
Pitton MB. MDCT versus MRI assessment of tumor response
after transarterial chemoembolization for the treatment of
hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;
33:532–540.
33. Abdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd
El-Wahab R. Reproducibility of LI-RADS treatment response
algorithm for hepatocellular carcinoma after locoregional
therapy. Diagn Interv Imaging 2020; 101:547–553.
34. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe
KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer
2000; 88:2452–2463.
35. Imai Y, Katayama K, Hori M, et al. Prospective comparison of
Gd-EOB-DTPA-enhanced MRI with dynamic CT for detecting recurrence of HCC after radiofrequency ablation. Liver
Cancer 2017; 6:349–359.
36. Granata V, Petrillo M, Fusco R, et al. Surveillance of HCC
patients after liver RFA: Role of MRI with hepatospecific contrast versus three-phase CT scan-experience of high volume
oncologic institute. Gastroenterol Res Pract 2013; 2013:469097.
37. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009; 10:25–34.
38. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med 2008; 359:378–390.
39. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib
Magnetic Resonance in Medical Sciences
Evaluation of Treatment Response of HCC
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:56–66.
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in
first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet 2018; 391:1163–1173.
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in
patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379:54–63.
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma
and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol 2019; 20:282–296.
Ronot M, Bouattour M, Wassermann J, et al. Alternative
response criteria (Choi, European association for the study
of the liver, and modified response evaluation criteria in solid
tumors [RECIST]) versus RECIST 1.1 in patients with
advanced hepatocellular carcinoma treated with sorafenib.
Oncologist 2014; 19:394–402.
Takada J, Hidaka H, Nakazawa T, et al. Modified response
evaluation criteria in solid tumors is superior to response
evaluation criteria in solid tumors for assessment of responses
to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 2015; 8:609.
van der Veldt AA, Meijerink MR, van den Eertwegh AJ,
Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell
cancer treated with sunitinib. Br J Cancer 2010; 102:803–809.
Choi H, Charnsangavej C, Faria SC, et al. Correlation of
computed tomography and positron emission tomography
in patients with metastatic gastrointestinal stromal tumor
treated at a single institution with imatinib mesylate: proposal
of new computed tomography response criteria. J Clin Oncol
2007; 25:1753–1759.
Gavanier M, Ayav A, Sellal C, et al. CT imaging findings in
patients with advanced hepatocellular carcinoma treated with
sorafenib: Alternative response criteria (Choi, European
Association for the study of the liver, and modified response
evaluation criteria in solid tumor [mRECIST]) versus RECIST
1.1. Eur J Radiol 2016; 85:103–112.
Tacher V, Lin M, Duran R, et al. Comparison of existing
response criteria in patients with hepatocellular carcinoma
treated with transarterial chemoembolization using a 3D
quantitative approach. Radiology 2016; 278:275–284.
Chapiro J, Wood LD, Lin M, et al. Radiologic-pathologic
analysis of contrast-enhanced and diffusion-weighted MR
imaging in patients with HCC after TACE: Diagnostic accuracy of 3D quantitative image analysis. Radiology 2014;
273:746–758.
Doemel LA, Chapiro J, Laage Gaupp F, et al. Reliable prediction
of survival in advanced-stage hepatocellular carcinoma treated
with sorafenib: Comparing 1D and 3D quantitative tumor
response criteria on MRI. Eur Radiol 2021; 31:2737–2746.
Zschäbitz S, Grüllich C. Lenvantinib: A tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR, KIT and RET. Recent
Results Cancer Res 2018; 211:187–198.
Matsumoto N, Ogawa M, Kaneko M, et al. Contrast-enhanced
ultrasonography for blood flow detection in hepatocellular
Vol. 22, No. 2
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
carcinoma during lenvatinib therapy. J Med Ultrason (2001)
2022; 49:425–432.
Kamachi N, Nakano M, Okamura S, et al. Evaluating the
therapeutic effect of lenvatinib against advanced hepatocellular
carcinoma by measuring blood flow changes using contrastenhanced ultrasound. Cancer Rep (Hoboken) 2022; 5:e1471.
Eso Y, Nakano S, Mishima M, et al. A simplified method to
quantitatively predict the effect of lenvatinib on hepatocellular
carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles. Quant Imaging Med Surg 2021;
11:2766–2774.
Chandarana H, Block TK, Rosenkrantz AB, et al. Free-breathing radial 3D fat-suppressed T1-weighted gradient echo
sequence: a viable alternative for contrast-enhanced liver imaging in patients unable to suspend respiration. Invest Radiol
2011; 46:648–653.
Ichikawa S, Motosugi U, Wakayama T, et al. An intra-individual comparison between free-breathing dynamic MR imaging
of the liver using stack-of-stars acquisition and the breathholding method using cartesian sampling or view-sharing.
Magn Reson Med Sci 2023; 22:221–231.
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med
2020; 382:1894–1905.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for
the treatment of hepatocellular carcinoma. Hepatology 2018;
67:358–380.
Vogel A, Martinelli E, Vogel A, et al. Updated treatment
recommendations for hepatocellular carcinoma (HCC) from
the ESMO Clinical Practice Guidelines. Ann Oncol 2021;
32:801–805.
Wright K. FDA approves nivolumab plus ipilimumab for the
treatment of advanced HCC. Oncology (Williston Park) 2020;
34:693606.
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients
with advanced hepatocellular carcinoma (CheckMate 040):
An open-label, non-comparative, phase 1/2 dose escalation
and expansion trial. Lancet 2017; 389:2492–2502.
Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as secondline therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase
III Trial. J Clin Oncol 2020; 38:193–202.
Cannella R, Lewis S, da Fonseca L, Ronot M, Rimola J.
Immunotherapy-based treatments of hepatocellular carcinoma: AJR expert panel narrative review. AJR Am J
Roentgenol 2022; 219:533–546.
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines
for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18:e143–e152.
Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3
determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44:793–798.
Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acidenhanced MR imaging—correlation with expression of sinusoidal and canalicular transporters and bile accumulation.
Radiology 2010; 255:824–833.
Kitao A, Matsui O, Yoneda N, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and
219
Y. Tsujita et al.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
220
signal intensity on gadoxetic acid-enhanced MR images.
Radiology 2012; 265:780–789.
Bressac B, Kew M, Wands J, Ozturk M. Selective G to T
mutations of p53 gene in hepatocellular carcinoma from
southern Africa. Nature 1991; 350:429–431.
de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and
human hepatocellular carcinomas. Proc Natl Acad Sci USA
1998; 95:8847–8851.
Sekine S, Ogawa R, Ojima H, Kanai Y. Expression of
SLCO1B3 is associated with intratumoral cholestasis and
CTNNB1 mutations in hepatocellular carcinoma. Cancer Sci
2011; 102:1742–1747.
Kitao A, Matsui O, Yoneda N, et al. Hepatocellular carcinoma
with β-catenin mutation: Imaging and pathologic characteristics. Radiology 2015; 275:708–717.
Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is
strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 2014; 61:1080–1087.
Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of
next-generation sequencing for matching patients to targeted
and immune therapies. Clin Cancer Res 2019; 25:2116–2126.
Kudo M. Gd-EOB-DTPA-MRI could predict WNT/β-catenin
mutation and resistance to immune checkpoint inhibitor
therapy in hepatocellular carcinoma. Liver Cancer 2020;
9:479–490.
Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of
immune microenvironment in hepatocellular carcinoma and
its additional impact on histological and molecular classification. Hepatology 2018; 68:1025–1041.
Morita M, Nishida N, Sakai K, et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver
Cancer 2021; 10:380–393.
Nishida N, Sakai K, Morita M, et al. Association between
genetic and immunological background of hepatocellular carcinoma and expression of programmed cell death-1. Liver
Cancer 2020; 9:426–439.
Aoki T, Nishida N, Ueshima K, et al. Higher enhancement
intrahepatic nodules on the hepatobiliary phase of Gd-EOBDTPA-enhanced MRI as a poor responsive marker of anti-
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
PD-1/PD-L1 monotherapy for unresectable hepatocellular
carcinoma. Liver Cancer 2021; 10:615–628.
Kurebayashi Y, Matsuda K, Ueno A, et al. Immunovascular
classification of HCC reflects reciprocal interaction between
immune and angiogenic tumor microenvironments.
Hepatology 2022; 75:1139–1153.
Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acidenhanced MRI of macrotrabecular-massive hepatocellular
carcinoma and its prognostic implications. J Hepatol
2021; 74:109–121.
Feng Z, Li H, Zhao H, et al. Preoperative CT for characterization of aggressive macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern in hepatocellular
carcinoma. Radiology 2021; 300:219–229.
Murai H, Kodama T, Maesaka K, et al. Multiomics identifies
the link between intratumor steatosis and the exhausted
tumor immune microenvironment in hepatocellular carcinoma. Hepatology 2023; 77:77–91.
Kubo A, Suda G, Kimura M, et al. Characteristics and lenvatinib treatment response of unresectable hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of
EOB-MRI. Cancers (Basel) 2021; 13:3633.
Kuwano A, Tanaka K, Yada M, et al. Therapeutic efficacy of
lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI. Mol
Clin Oncol 2022; 16:53.
Fujii Y, Ono A, Hayes CN, et al. Identification and monitoring
of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. J Exp Clin Cancer Res
2021; 40:215.
Sasaki R, Nagata K, Fukushima M, et al. Evaluating the role of
hepatobiliary phase of gadoxetic acid-enhanced magnetic
resonance imaging in predicting treatment impact of lenvatinib and atezolizumab plus bevacizumab on unresectable hepatocellular carcinoma. Cancers (Basel) 2022; 14:827.
Yamauchi M, Ono A, Ishikawa A, et al. Tumor fibroblast
growth factor receptor 4 level predicts the efficacy of lenvatinib in patients with advanced hepatocellular carcinoma. Clin
Transl Gastroenterol 2020; 11:e00179.
Kawamura Y, Kobayashi M, Shindoh J, et al. Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma
may be a useful new predictor of early response to lenvatinib
and overall prognosis. Liver Cancer 2020; 9:275–292.
Magnetic Resonance in Medical Sciences
...
論文の公開元へ
